Saab has unveiled an all new medical treatment simulator named WE:Treat.
WE:Treat is the next generation of Saab’s medical treatment simulator, allowing the user to train medical personnel in handling injured soldiers out in field. The interface is based on a new app for smartphones and tablets. The application, WE:Treat, is based on cooperation between fourteen countries that are members in the Interoperability User Community (IUC).
Operators will receive training in prioritizing patients and providing medical care. It is based on a medical treatment database that lets the software determine the seriousness of a soldier’s wound from the hit location, wound severity and ammunition type.
“With our new WE:Treat application the users will train on handling injured soldiers in the field, closer to real-life and with more treatment options and scenarios than ever before. We are proud to unveil WE:Treat, Saab’s most advanced Medical Treatment Simulator yet”, says Åsa Thegström, head of business unit Training & Simulation at Saab´s business area Dynamics.
All activities for each medic are available in the evaluation tool WinEXCON for further analysis. This gives the training unit the possibility to perform an AAR for all medic operators participating in the exercise. The statistical reports include:
• How much time a medic operator has spent on each patient
• The time it has taken to be transported through the medical chain
• A medical summary of examinations and treatments performed by each medic
• Measurement of Platinum Ten and Golden hour*
* Platinum Ten refers to the first 10 minutes of arrival of the medics. The Golden hour refers to the first 60 minutes after the injury.
Saab has delivered medical training capability to several customers for more than ten years. WE:Treat is the latest generation medical treatment simulator, giving the user ability to display wound information, and perform examinations and treatments.
WE:Treat will be presented during I/ITSEC 26-29 November, at Saab’s stand #2449 in Orlando, Florida.